Natera, Inc. (NTRA)
NASDAQ: NTRA · Real-Time Price · USD
157.70
-2.11 (-1.32%)
At close: Aug 13, 2025, 4:00 PM
158.00
+0.30 (0.19%)
After-hours: Aug 13, 2025, 7:45 PM EDT
Natera Employees
Natera had 4,434 employees as of December 31, 2024. The number of employees increased by 1,141 or 34.65% compared to the previous year.
Employees
4,434
Change (1Y)
1,141
Growth (1Y)
34.65%
Revenue / Employee
$442,997
Profits / Employee
-$57,113
Market Cap
21.64B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 4,434 | 1,141 | 34.65% |
Dec 31, 2023 | 3,293 | 275 | 9.11% |
Dec 31, 2022 | 3,018 | 348 | 13.03% |
Dec 31, 2021 | 2,670 | 855 | 47.11% |
Dec 31, 2020 | 1,815 | 776 | 74.69% |
Dec 31, 2019 | 1,039 | 64 | 6.56% |
Dec 31, 2018 | 975 | 82 | 9.18% |
Dec 31, 2017 | 893 | 41 | 4.81% |
Dec 31, 2016 | 852 | 136 | 18.99% |
Dec 31, 2015 | 716 | 42 | 6.23% |
Dec 31, 2014 | 674 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
NTRA News
- 5 days ago - Natera shares surge 17% after strong Q2 results and upgraded guidance - Invezz
- 6 days ago - Natera, Inc. (NTRA) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - Natera Reports Second Quarter 2025 Financial Results - Business Wire
- 6 days ago - Natera Launches Fetal Focus™: A Noninvasive Prenatal Test for Inherited Conditions - Business Wire
- 12 days ago - Natera Highlights Latest Prospera™ Data at WTC 2025; 16 Abstracts Including Five Oral Presentations - Business Wire
- 13 days ago - Natera to Report Its Second Quarter Results on August 7, 2025 - Business Wire
- 15 days ago - Natera Announces Launch of ABCSG 61 (“TEODOR”), a Randomized Controlled Trial of Signatera™ in Early-Stage Breast Cancer - Business Wire
- 20 days ago - PEDAL Study Successful, Shows Monitoring with Prospera™ Kidney Provides Accurate Prognosis of Long-Term Clinical Outcomes Following Rejection; Now Published in AJT - Business Wire